Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Insulin- and Glucose Metabolism in Pulmonary Arterial Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03584607
Recruitment Status : Completed
First Posted : July 12, 2018
Last Update Posted : January 27, 2020
Sponsor:
Information provided by (Responsible Party):
Medical University of Graz

Brief Summary:
Insulin resistance is a key mechanism in metabolic disorders, which has also been implicated in the development of pulmonary hypertension. In this pilot study, the investigators´ goal is to directly determine insulin sensitivity in idiopathic pulmonary arterial hypertension patients and to compare the results with data from healthy controls.

Condition or disease
Insulin Resistance

Layout table for study information
Study Type : Observational
Actual Enrollment : 10 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Insulin- and Glucose Metabolism in Pulmonary Arterial Hypertension - a Pilot Study
Actual Study Start Date : December 20, 2017
Actual Primary Completion Date : February 11, 2019
Actual Study Completion Date : February 11, 2019


Group/Cohort
Idiopathic Pulmonary Arterial Hypertension patients
Blood sampling Insulin resistance-measurement
Healthy controls
Blood sampling Insulin resistance-measurement



Primary Outcome Measures :
  1. Insulin resistance [ Time Frame: 1 day ]
    Determination of insulin sensitivity using hyperinsulinemic-euglycemic clamp technique



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Healthy controls, or patients with idiopathic or hereditary pulmonary hypertension
Criteria

Inclusion Criteria:

  • signed informed consent form
  • patients with idiopathic or hereditary pulmonary hypertension / healthy controls

Exclusion Criteria:

  • premenopausal women
  • other relevant lung disease
  • relevant left heart disease
  • untreated systemic hypertension
  • Diabetes mellitus
  • pulmonary hypertension other than idiopathic or hereditary form

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03584607


Locations
Layout table for location information
Austria
Medical University Graz, Division of Pulmonology
Graz, Steiermark, Austria, 8010
Sponsors and Collaborators
Medical University of Graz
Investigators
Layout table for investigator information
Principal Investigator: Bence M. Nagy, PhD Medical University of Graz
Layout table for additonal information
Responsible Party: Medical University of Graz
ClinicalTrials.gov Identifier: NCT03584607    
Other Study ID Numbers: 29-066 ex 16/17
First Posted: July 12, 2018    Key Record Dates
Last Update Posted: January 27, 2020
Last Verified: January 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Insulin Resistance
Vascular Diseases
Cardiovascular Diseases
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases